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INVITED REPORT OF A WORKSHOP
Consensus Guidelines for the Diagnosis and Treatment
of Adults with Growth Hormone Deficiency: Summary
Statement of the Growth Hormone Research Society
Workshop on Adult Growth Hormone Deficiency*
Based on the increasing body of evidence that adults with
GH deficiency (somatotropin deficiency) have impaired
health that improves with GH replacement, many countries
have already approved the use of GH for replacement ther-
apy in adults with GH deficiency. To ensure that patients are
appropriately identified and treated, the Growth Hormone
Research Society (GRS) convened a workshop on April 14–
17, 1997, in Port Stephens, Australia, to formulate consensus
guidelines for the diagnosis and treatment of adults with GH
deficiency. The GRS invited scientists with expertise in the
field, representatives from industry involved in the manu-
facture of recombinant human GH, and representatives from
health authorities from a number of countries to attend the
workshop, all of whom contributed to the consensus guide-
lines as detailed below.
Diagnosis of GH Deficiency in Adults
Definition of adult GH deficiency
Severe GH deficiency should be defined biochemically
within an appropriate clinical context. In patients with
hypothalamic-pituitary disease, the syndrome of adult GH
deficiency characteristically presents with alterations in body
composition, including reduced lean body mass and bone
mineral density and increased fat mass with a preponder-
ance of abdominal adiposity (increased waist circumference).
The skin is thin and dry, and sweating is reduced. Muscle
strength and exercise performance are reduced. An impaired
sense of well-being and other psychological complaints are
common. Partial GH deficiency exists, but further research is
needed to distinguish it from physiological causes of reduced
GH secretion, e.g. aging. Furthermore, the benefits of treat-
ment of partial GH deficiency remain to be established.
Patients who should be tested for adult GH deficiency
An evaluation for GH deficiency should be considered
only in patients with evidence of hypothalamic-pituitary
disease, subjects who have received cranial irradiation, or
patients with childhood onset of GH deficiency. In patients
with organic hypothalamic-pituitary disease, the likelihood
of GH deficiency increases with the increasing number of
pituitary hormone deficits from approximately 45% if no
other deficits are present to nearly 100% if three or four
pituitary hormone deficiencies are present. It may not be
necessary to evaluate patients with pituitary microadenomas
for GH deficiency unless other pituitary hormone deficits are
present or unless a strong clinical suspicion of GH deficiency
exists. Patients with childhood-onset GH deficiency should
be retested as adults before committing them to long term
GH replacement.
Biochemical diagnosis of adult GH deficiency
Dynamic tests of GH secretion. The diagnosis of adult GH
deficiency is established by provocative testing of GH se-
cretion. Patients should be receiving stable and adequate
hormone replacement for other hormonal deficits before test-
ing. At present, the insulin tolerance test is the diagnostic test
of choice. Provided adequate hypoglycemia is achieved, this
test distinguishes GH deficiency from the reduced GH se-
cretion that accompanies normal aging and obesity. The in-
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sulin tolerance test should be performed in experienced en-
docrine units where the test is performed frequently. The test
is contraindicated in patients with electrocardiographic ev-
idence or history of ischemic heart disease or in patients with
seizure disorders. Given these precautions, the insulin tol-
erance test is safe; however, there is less experience in pa-
tients over the age of 60 yr.
Most normal subjects respond to insulin-induced hypo-
glycemia with a peak GH concentration of more than 5 mg/L.
Severe GH deficiency is defined by a peak GH response to
hypoglycemia of less than 3 mg/L. These cut-off values were
defined in GH assays employing polyclonal competitive
RIAs. However, GH immunoassay results vary between dif-
ferent methods, and therefore, the cut-off value may need to
be adjusted appropriately (see below for standardization of
assays).
In patients with contraindications to the insulin tolerance
test, alternative provocative tests of GH secretion must be
used with appropriate cut-offs. At present, the combined
administration of arginine and GHRH is the most promising
alternative. Administration of arginine alone or glucagon
alone can be considered, but these tests have less established
diagnostic value compared to the insulin tolerance test.
Other stimulatory tests may prove to be useful, but require
further validation. The present data indicate that the
clonidine test is less useful in adults than in children.
Adult patients with hypothalamic-pituitary disease and
one or more additional pituitary hormone deficits require
only one provocative test of GH secretion for the diagnosis
of GH deficiency. Childhood-onset GH deficiency requires
reconfirmation in adulthood. To establish the diagnosis of
isolated GH deficiency in adults, it is recommended that, in
addition, a second biochemical test of GH status be
abnormal.
Biochemical markers of GH action. Several biochemical markers
of GH action have been studied to determine their diagnostic
potential in adult GH deficiency. Serum insulin-like growth
factor I (IGF-I) concentrations are only useful when age-
adjusted normal ranges are available. In adults, a normal
serum IGF-I does not exclude the diagnosis of GH deficiency.
A serum IGF-I below the normal range is suggestive of GH
deficiency in the absence of other conditions known to lower
serum IGF-I levels; for example, malnutrition, hepatic dis-
ease, poorly controlled diabetes mellitus, and hypothyroid-
ism. In the presence of multiple (two or more) pituitary
hormone deficiencies, a low serum IGF-I level indicates a
high probability of GH deficiency. However, it is recom-
mended that the diagnosis of adult GH deficiency be con-
firmed by a provocative test of GH release.
Measurement of serum IGF-binding protein-3 or acid-
labile subunit has to date not proven to offer any advantage
over the measurement of serum IGF-I.
Standardization of assays
GH immunoassay results vary between different assay
methods. The above recommendations for cut-off values for
the insulin tolerance test are based on results obtained with
polyclonal competitive RIAs calibrated against the pituitary-
derived preparation International Reference Preparation
(IRP) 80/505 (1 mg 5 2.6 U). The GRS advocates future use
of the recombinant hGH preparation IRP 88/624 (1 mg 5 3.0
U). Further comparative studies are necessary at both na-
tional and international levels to achieve standardization of
GH assays.
The presence of IGF-binding proteins interfere with mea-
surement of serum IGF-I. At present, removal of IGF-binding
proteins before immunoassay is essential. However, new
IGF-I assays are being developed that may not require ex-
traction procedures. The current international reference stan-
dard for IGF-I assays is IRP 87/518. GH and IGF-I results
should be expressed in mass units.
Treatment of GH Deficiency in Adults
Patients to be treated
All patients with documented severe GH deficiency are
eligible for GH replacement. The goal for GH replacement in
adults is to correct the abnormalities associated with adult
GH deficiency.
Dose selection
The objective of treatment is to maximize benefit and min-
imize side-effects. Experience has shown that sensitivity to
GH treatment varies considerably between individuals, with
elderly individuals being the most sensitive. It is recom-
mended that therapy should start with a low dose (0.15–0.30
mg/day; 0.45–0.90 IU/day). The dosage should be increased
gradually on the basis of clinical and biochemical responses
and no more frequently than at monthly intervals. The main-
tenance dose may vary considerably from person to person
and seldom exceeds 1.0 mg/day (3 IU/day).
In healthy adults it is known that premenopausal women
secrete more GH than age-matched men, and that GH se-
cretion is reduced with advancing age and with obesity. In
adults aged 30–50 yr, the reported daily production of GH
in women was approximately 0.2 mg/day, whereas the pro-
duction rate in men was approximately 0.1 mg/day. Clinical
experience has demonstrated that the variability in sc ab-
sorption and individual responsiveness to GH make dose
determination based on body weight or body surface area
less helpful than anticipated. Furthermore, some adult pa-
tients experience side-effects even with a low dose.
In accordance with the clinical practice of treating GH-
deficient children, we recommend that GH be administered
as daily sc self-injections in the evening.
Monitoring treatment efficacy
A physical examination and a careful clinical history with
particular attention to quality of life-related questions are of
great value in monitoring treatment. Where appropriate,
questioning the patient’s partner may also assist with the
evaluation.
At present, the best biochemical marker of GH action is
IGF-I in serum. An important use of IGF-I measurements is
to avoid overreplacement, and values should be kept in the
age-related normal range. IGFBP-3 has been found to be less
useful, whereas acid-labile subunit, although promising,
needs further validation. In the initial stages of dose titration,
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frequent measurements are required (every 1 or 2 months).
Once a stable dose has been reached, once or twice yearly
measurements are sufficient.
Simple anthropometric measures, such as weight and
waist circumference, may be supplemented by bioelectrical
impedance or dual x-ray absorptiometry; the latter is par-
ticularly valuable when bone mineral density is reduced.
Lipids should be monitored annually.
Safety issues
Adult GH deficiency is associated with reduced extracel-
lular fluid volume. Fluid retention during GH treatment is,
therefore, to be expected, and the patient should be informed.
Edema and occasionally carpal tunnel syndrome may be
seen. These symptoms are usually transient and dose de-
pendent, but may require a dose reduction. Mild arthralgias
may occur, but are usually self-limiting. Because GH may
reduce insulin sensitivity, markers of glycemia should be
monitored periodically.
The risk of certain malignancies, in particular colon cancer,
is increased in acromegaly. It is, however, inappropriate to
extrapolate from the acromegalic data to the GH-replaced
adult with hypopituitarism. Nonetheless, current recom-
mendations for cancer prevention and early detection in the
general population should be implemented.
Good clinical practice requires regular imaging of residual
pituitary tumor; GH replacement does not impose a need for
intensifying this follow-up. A baseline scan is recommended
before starting treatment.
GH influences the metabolism of many substances, in-
cluding other hormones and medications; therefore, alter-
ations in the dose requirements of such compounds should
be anticipated.
Contraindications
Absolute contraindications include active malignancy, be-
nign intracranial hypertension, and proliferative or prepro-
liferative diabetic retinopathy. Early pregnancy is not a con-
traindication, although GH should be discontinued in the
second trimester as GH is produced by the placenta.
Long-term care
Although insufficient information is available at present,
GH replacement (as with other hormones) is most likely for
life. It is possible that the dose requirement may decrease
over time. Replacement therapy in the elderly should be
monitored particularly carefully as the patient ages, with
special emphasis on dosage and perceived benefit. If any
patient perceives no benefit, then a trial of withdrawal
should be considered.
It is recommended that patients with hypopituitarism re-
ceiving GH replacement should remain under long term
surveillance by an endocrinologist with special experience in
pituitary disease; this can be undertaken in partnership with
an internist or general practitioner.
Patients may need initially to be seen initially by the en-
docrinologist as often as monthly. Once treatment is stabi-
lized, one or two visits per year will suffice.
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